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Recent years have seen an increase of the use of imaging 
and fluid biomarkers as a key tool to help in the differential 
diagnosis of Alzheimer’s disease (AD), especially in its 
pre-dementia stages (1). 
In AD clinical practice, fluid biomarkers are currently 
focused on beta-amyloid and tau species assessment in 
the cerebrospinal fluid (CSF) and the development and 
standardization of this approach led over the years to an 
increased understanding of the AD neuropathological 
cascade, a paradigm shift in clinical trials recruitment 
strategies and improved diagnostic accuracy in daily clinical 
practice (2). CSF biomarkers, however, are ill-suited to 
be used as a screening tool in the general population or to 
monitor patients over time, leading to multiple approaches 
to develop blood-based markers for AD (3) albeit with 
limited success due to the lower concentration of the 
target proteins in blood compared to CSF, the interference 
of other plasma proteins and the presence of degrading 
proteases, which are all variables of difficult analytical 
management (4). 
In such scenario, a promising serum-based biomarker of 
neural damage currently extensively evaluated in a number 
of neurological conditions, is represented by neurofilament 
light chain (NfL) level assessment (5). NfL is a cytoskeleton 
protein expressed in large caliber myelinated axons, and 
it is released in the extra-cellular fluid as consequence of 
axonal damage. Thus, while other fluid markers such as 
beta-amyloid and tau are aimed to help in the diagnosis 
of a specific clinical conditions (i.e., AD), NfL is instead a 
trans-diagnostic marker of neurodegeneration. The broad 
applicability of serum NfL assessment to a number of 
different neurological conditions as well as the commercial 
availability of sensitive assays for its assessment in serum 
and CSF (6) make NfL an attractive putative serum-based 
marker of neurodegeneration also in AD.  
In an issue of Nature Medicine, Preische et al. (7) 
evaluated NfL level over time in pre-symptomatic AD 
mutation carriers, non-carriers (used as a control group) 
and symptomatic carriers and evaluated both cross sectional 
CSF and serum NfL levels as well as longitudinal changes 
in serum NfL levels over time. In line with previous 
reports (8,9), NfL levels in serum and CSF were strongly 
correlated in all patients, but the strength of the observed 
association increased the confidence in the interpretation of 
the longitudinal serum NfL data. Taking into account cross 
sectional serum NfL values, a significant difference between 
pre-symptomatic mutation carriers and controls was evident 
at 6.8 years before estimated onset in carriers, while using 
the yearly rate of change in serum NfL the difference 
between carriers and non-carriers was evident at least a 
decade earlier. Serum NfL rate of change, moreover, closely 
reflected progressive atrophy in a specific AD-associated 
area (i.e., the precuneus) and changes in cognition. 
Interestingly from a pathophysiological perspective, 
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the rate of change of serum NfL peaked in carriers during 
the conversion phase to clinically evident cognitive 
impairment (i.e., those asymptomatic patients who became 
symptomatic at follow-up visits) and reached a plateau 
in symptomatic carriers, even if absolute values of NfL 
tended to slowly increase over time. A similar pattern of 
longitudinal concentration changes has been also reported 
for other CSF or blood proteins, such as those reflecting 
brain neuroinflammation (10,11) and proposed as possible 
evidence of microglia activation in the earliest phase of AD 
(12,13). These data suggest that longitudinal serum NfL 
assessment, associated with the evaluations of other serum 
and CSF components, could represent a useful tool to study 
in vivo the cascade leading to neurodegeneration. 
Indeed, also taking into account that the elevation of 
serum NfL values in AD—either familiar or sporadic—
has already been reported in the literature (2,14,15), the 
presence of robust longitudinal assessment of NfL levels 
and of their rate of change over time represents the most 
novel finding provided by the work of Preische et al. (7). 
In an ideal and yet-to-come general population screening 
for neurodegenerative conditions, serum NfL could be the 
first test to perform given its high negative predictive value 
(3,16); and if elevated could be followed by other diagnostic 
biomarkers to confirm the presence of neurodegeneration 
and to define the underlying process and its prognosis. 
The data presented by Preische and colleagues, however, 
suggest that longitudinal rather than cross-sectional serum 
NfL values could be more informative given its increased 
sensibility, possibly due to inter-individual differences in 
baseline serum NfL levels and the possible—but transient-
impact on serum NfL levels of non-neurodegenerative 
brain injuries such as trauma or stroke (5). The application 
of serum NfL as a tool to screen for neurodegeneration in 
the general population, however, is still to come, both given 
the lack of current disease modifying treatments for these 
conditions and the uncertainties regarding the timing of 
serum NfL changes in sporadic neurodegeneration. 
If the application of serum NfL as a screening test is 
not yet ready for clinical use, the time is almost ripe to 
apply this tool in the diagnostic pathway of mild cognitive 
impairment (MCI) of unknown origin in association with 
other biomarkers (15), as well as an outcome marker in 
clinical trials to assess the response to a disease-modifying 
drug, in line with what is currently proposed in other 
neurological conditions such as multiple sclerosis (17). 
To reach these aims, however, efforts are needed to reach 
a standardization of pre-analytic and analytical procedures, 
to longitudinally explore the dynamic changes in sporadic 
AD as well as in other neurodegenerative conditions and 
to evaluate the possible additional or alternative diagnostic 
role of other CNS-derived serum proteins. Despite these 
considerations, the work of Preische and colleagues 
represent a key step in the development and validation of 
a clinically-relevant approach to assess neurodegeneration 
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